2006 Industry Dynamics: Lessons to Be Learned

Stunning successes and startling failures highlight 2006's pharmaceutical industry. In this year-end retrospective report, we contemplate the importance of these developments and what they mean to the pharmaceutical industry. Additionaly, we asked industry experts for their opinions and integrated their commentary and analysis into this report. Get the Answers You Need to Shape Your Strategy The winning technology of 2006 continues to be a major success for the drug industry; however, even successful and well-tried innovations can meet with disaster. Which technology has Decision Resources deemed most lucrative in 2006, and why is its potential for commercial success so great? Which particular agent proves that even the most promising technologies are not immune to the risks inherent in development? 2006 saw more development and deals within a group of products that is poised to dramatically change the way diseases are currently treated. What is this group of products, and what were the major business strategies and deals within this group in 2006? Competition between innovator companies and generics companies has never been higher as these groups battle to control drug markets; innovator companies continue to face unrelenting pressure from generics companies that want to invalidate drug patents and gain early market entry for their drugs. What were 2006's developments on the generics front line? What strategies are innovator companies employing to ward off generics competition? A prominent strategy of the pharmaceutical industry-historically employed to bolster thin product pipelines and increase presence in more markets-continues in 2006. However, this strategy is threatening the productivity and innovation of the largest pharmaceutical manufacturers. What longstanding practice in the pharmaceutical industry is counterproductive in today's industry? How may the recent decisions of one major company serve as a lesson? Please note, the PDF e-mail from publisher version of this report is for a global site license.

Additional Information


Companies Mentioned in This Spectrum Report

Abbott Laboratories
Abgenix
Abmaxis
Abrika Pharmaceuticals
Actavis
Akzo Nobel
Allen
Allergan
Alnylam Pharmaceuticals
Altana
Amgen
Apotex
Astex Therapeutics
AstraZeneca
Banyu Pharmaceuticals
Barr Pharmaceuticals
Baxter
Bayer
Be-Tabs Pharmaceuticals
Betapharm
Biogen Idec
Biomarin Pharmaceutical
Boston Scientific
Bristol-Myers Squibb
Cambridge Antibody
Technology
Conor Medsystems
Dr. Reddy’s Laboratories
Elan
Ethimed
Genentech
Greenstone
Guidant
Hospira
ImClone
Ivax
John Ansell Consultancy
Johnson & Johnson
King PLLC
Lehman Brothers
Mayne Pharmaceuticals
Merck
Merck KGaA
Merck-Serono
Biopharmaceuticals
Millennium Research
Group
Monogram Biosciences
Mundogen
Neurocrine Biosciences
NicOx
Novartis Ophthalmics
Noxxon Pharma
Nycomed
Odyssey Thera
Orthovita
Oscient Pharmaceuticals
OSG Norwich
Par
Pfizer
Pfizer Consumer
Healthcare
Pharma Strategy
Consulting
Pliva
PowderMed
Procter & Gamble
Quark Biotech
Ranbaxy Laboratories
Rinat Neuroscience
Roche
Sandoz
Sanofi -Aventis
Savient
Schering-Plough
Schwarz Pharma
Sekhsaria Chemicals
Shionogi
Spectrum
Tanabe
TeGenero
Tepnel
Terapia
Teva Pharmaceuticals
Tianjin Hualida
Biotechnology
TransTech Pharma
Uso Racional
Watson Pharmaceuticals